White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin

K. Egger, C. Clemm von Hohenberg, M. F. Schocke, C. R. G. Guttmann, D. Wassermann, M. C. Wigand, W. Nachbauer, C. Kremser, B. Sturm, B. Scheiber-Mojdehkar, M. Kubicki, M. E. Shenton, S. Boesch

Download full paper


Erythropoietin (EPO) has received growing attention because of its neuroregenerative properties. Preclinical and clinical evidence supports its therapeutic potential in brain conditions like stroke, multiple sclerosis, and schizophrenia. Also, in Friedreich ataxia, clinical improvement after EPO therapy was shown. The aim of this study was to assess possible therapy-associated brain white matter changes in these patients.


Egger K, von Hohenberg CC, Schocke MF, Guttmann CRG, Wassermann D, Wigand MC, Nachbauer W, Kremser C, Sturm B, Scheiber-Mojdehkar B, Kubicki M, Shenton ME, Boesch S. White matter changes in patients with friedreich ataxia after treatment with erythropoietin. J NEUROIMAGING 2013;.

Research area

© 2013 Psychiatry Neuroimaging Laboratory | Last updated 04.15.2013